TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6565475
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for ten days
Study: 15625212
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate
Study: 12407605
Drug: High-dose AF0144
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AF0144 (2.7 g/kg)
Study: 12407605
Drug: Low-dose AF0144
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AF0144 (1.8 g/kg)
Study: 27144828
Drug: Stem cells
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cells cultured on β‐TCP in combination with rh‐PDGF‐BB
Study: 24080653
Drug: motavizumab‐YTE (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: motavizumab‐YTE (0.3, 3, 15, or 30 mg/kg)
Study: 21068692
Drug: Hib-MenC-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenC-TT vaccine
Study: 14768922
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Study: 14768922
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Study: 2788001
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation with naloxone (50 mg)
Study: 358815
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous digoxin
Study: 358815
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg intravenous digoxin
Study: 358815
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg intravenous digoxin
Study: 28494047
Drug: Immediately Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately Loaded Implants (IL)
Study: 28494047
Drug: Delayed Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Loaded Nonsubmerged Implants (NS)
Study: 28494047
Drug: Delayed Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Loaded Submerged Implants (SI)
Study: 23849964
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (chronic statin therapy without reloading)
Study: 16448524
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg/day) plus metformin (1500 mg/day)
Study: 16448524
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) plus metformin (1500 mg/day)
Study: 10697061
Drug: Oseltamivir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 150 mg twice daily
Study: 8222517
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose polymer solution (272 +/- 1.1 mosmol/kg)
Study: 8222517
Drug: 7.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% glucose polymer solution (277 +/- 2.0 mosmol/kg)
Study: 8222517
Drug: 1.36% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.36% glucose solution (339 +/- 1.9 mosmol/kg)
Study: 8222517
Drug: 2.27% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.27% glucose solution (393 +/- 3.2 mosmol/kg)
Study: 8222517
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose polymer solution (284 +/- 2.0 mosmol/kg)
Study: 8222517
Drug: 3.86% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.86% glucose solution (482 +/- 1.6 mosmol/kg)
Study: 8222517
Drug: 7.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% glucose polymer solution with 0.35% glucose
Study: 30515390
Drug: Coconut water
Normalized name: COCONUT WATER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut water (2L daily for 4 days)
Study: 16083628
Drug: Vitamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin treatment (group A, n = 18, folic acid 5 mg/d, vitamin B(6) 50 mg/d, B(12) 1000 microg/d)
Study: 12064916
Drug: Deferiprone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (75 mg/kg/day)
Study: 12064916
Drug: Deferoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (50 mg/kg/day)
Study: 9793811
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 mcg/kg (C5)
Study: 9793811
Drug: Clonidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 2.5 mcg/kg (C2.5)
Study: 9793811
Drug: Diazepam 100
Normalized name: diazepam 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 100 mcg/kg (D)
Study: 7543785
Drug: Fotemustine (FM)
DrugBank: Fotemustine (DB04106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine (FM) 100 mg/m2 on days 1 + 8 + 15, followed by maintenance courses (q3w)
Study: 2877570
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at bedtime
Study: 2696659
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg single dose
Study: 825895
Drug: 1000 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mug TRH (thyrotropin releasing hormone) by slow, continuous infusion over 4 hours
Study: 28691141
Drug: Vinpocetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine (30 mg per day intravenously for 14 consecutive days)
Study: 20121770
Drug: 0.11 ml.mm(‐2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.11 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (low volume)
Study: 20121770
Drug: 0.4 ml.mm(‐2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (high volume)
Study: 6121043
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of lorazepam (2 mg)
Study: 6121043
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of lorazepam (2 mg)
Study: 6121043
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (2 mg) from oral tablets
Study: 6121043
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (2 mg) from specially formulated tablets
Study: 6121043
Drug: Intramuscular, oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular, oral, and sublingual lorazepam (2 mg)
Study: 24756903
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) therapy
Study: 17445955
Drug: HPV-16 vaccine
Normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16 vaccine (three-dose regimen)
Study: 12236023
Drug: SB-LOT (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-LOT (90 mg coumarin and 540 mg troxerutin per day)
Study: 2405915
Drug: Vasopressin nasal
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin nasal spray administered q.i.d. from the first through the fifth ECT
Study: 9569075
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (OP)
Study: 25406226
Drug: Written materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written materials plus nicotine replacement therapy (NRT)
Study: 24942849
Drug: Automated bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated bolus delivery of 0.2% ropivacaine (4 mL) with PRN boluses (5 mL, lockout 30 min)
Study: 24942849
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% ropivacaine (4 mL/h) with PRN boluses (5 mL, lockout 30 min)
Study: 15220019
Drug: Fixed-combination dorzolamide/timolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination dorzolamide/timolol, 1 drop in the affected eye BID (morning and evening)
Study: 9353612
Drug: Transcutaneous electrotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrotherapy (H-Wave machine, pulse width 4 ms, 25-35 V, > or = 2 Hz, 30 min daily for 4 weeks)
Study: 9353612
Drug: Transcutaneous electrotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrotherapy (after sham treatment)
Study: 8144852
Drug: Metyrapone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (750 mg orally at 08:00 h on day 1 and at 4 hourly intervals over a 24-h period)
Study: 8144852
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg tablet)
Study: 3018023
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 250 micrograms Cosyntropin (ACTH‐(1‐24))
Study: 3018023
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 250 micrograms Cosyntropin (ACTH‐(1‐24))
Study: 31774626
Drug: Intranasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells (500,000 cells per 20 μL)
Study: 31774626
Drug: Intranasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal delivery of human umbilical cord Wharton's jelly mesenchymal stromal cells
Study: 30683494
Drug: Conventional anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-inflammatory treatment plus colchicine for 3 months
Study: 30683494
Drug: Conventional anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-inflammatory treatment only
Study: 26181174
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (E+P) - 0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate
Study: 26181174
Drug: Estrogen alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen alone - 0.625 mg/d conjugated equine estrogens
Study: 19414982
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agent (OHA)
Study: 14737055
Drug: G‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF at 5 Kg/kg for established febrile neutropenia (Group A)
Study: 14737055
Drug: G‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF at 263 Kg/day if ANC was 1500/microl or less (Group B)
Study: 8032072
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (0.4 mg/kg)
Study: 8032072
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (0.6 mg/kg)
Study: 3689065
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily) plus aspirin (650 mg four times daily)
Study: 3689065
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (650 mg four times daily)
Study: 26301448
Drug: Risperidone monotherapy
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone monotherapy
Study: 29482256
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (5mg and 10mg)
Study: 27302126
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) 20 mL/kg intravenous
Study: 27302126
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrate (PCC) 30 IU/kg intravenous
Study: 18940711
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (a rest hour)
Study: 16161468
Drug: Placebo-control compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control compound
Study: 1617799
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone at 0 minutes
Study: 1617799
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 0 minutes and arginine at 0-30 minutes
Study: 29364033
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy (7-minute treatment with four 2-in cups on trigger points in hamstring)
Study: 1939676
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (Control)
Study: 22853619
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Traditional Chinese Medicine (TCM) for four cycles, administered every 3 weeks.
Study: 22853619
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (placebo) for four cycles, administered every 3 weeks.
Study: 17971598
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) 30 Gy; 2 Gy daily fractions
Study: 7928814
Drug: Cefprozil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (20 mg/kg/day bd)
Study: 7928814
Drug: Amoxycillin/clavulanate (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (13.3 mg/kg/day tid)
Study: 2813153
Drug: Acetaminophen 600
Normalized name: acetaminophen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 600 mg with Codeine 60 mg
Study: 1096923
Drug: Azaribine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azaribine at 200 mg/kg a day
Study: 1096923
Drug: Azaribine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azaribine at 125 mg/kg a day
Study: 27655703
Drug: Ongoing chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing chemotherapy
Study: 22071709
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin (rhleptin) infusion for 4 hours
Study: 22071709
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) infusion for 4 hours
Study: 19192474
Drug: Medication (Nefazodone)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Nefazodone)
Study: 15327610
Drug: LUNA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUNA with laparoscopic surgical treatment of endometriosis
Study: 15327610
Drug: No LUNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No LUNA with laparoscopic surgical treatment of endometriosis
Study: 8937934
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg daily)
Study: 3479329
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 75 mg/m2 every 3 weeks
Study: 3479329
Drug: 4-epiadriamycin (EPI)
Normalized name: 4'-Epiadriamycin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-epiadriamycin (EPI) 75 mg/m2 every 3 weeks
Study: 28403472
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation treatment combined with standard cognitive-behavioral smoking cessation (ERT + CBT)
Study: 16291802
Drug: fMRI signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: fMRI signal changes in the posterior parietal cortex (PPC) during memory of target locations; no specific dosage or duration mentioned.
Study: 16291802
Drug: Memory of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory of two sequentially flashed targets presented in either the same or different visual hemifields; no specific dosage or duration mentioned.
Study: 8281852
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg
Study: 15182896
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management (MM)
Study: 24999076
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment aiming for a target systolic blood pressure of 120-140 mmHg
Study: 24999076
Drug: Conservative antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative antihypertensive treatment as recommended by guidelines for 7 days
Study: 24999076
Drug: Conservative antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative antihypertensive treatment
Study: 22859825
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of quadrivalent human papillomavirus vaccine (QHPV)
Study: 22859825
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of quadrivalent human papillomavirus vaccine (QHPV)
Study: 18514933
Drug: Yoga treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga treatment (YT)
Study: 18514933
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (MT)
Study: 16200819
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (200 microg once daily)
Study: 16200819
Drug: Levocabastine hydrochloride
Normalized name: Levocabastine Hydrochloride
DrugBank: Levocabastine (DB01106)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocabastine hydrochloride (200 microg twice daily)
Study: 16200819
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (5.6 mg 4 times daily)
Study: 9475262
Drug: molsidomine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine (6 mg/h)
Study: 9475262
Drug: isosorbide-5-mononitrate (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: isosorbide-5-mononitrate (3.75 mg/h)
Study: 8574314
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy aimed at increasing vocal and respiratory effort (VR)
Study: 8574314
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy aimed at increasing respiratory effort (R)
Study: 2677866
Drug: Monsel's solution
Normalized name: Monsel's solution
DrugBank: Ferric subsulfate (DB13885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monsel's solution and vaginal pack (non-suture technique)
Study: 389839
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg vs Propranolol 80 mg
Study: 27131077
Drug: Daily boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily boost of 0.5 Gy to the tumor bed
Study: 27131077
Drug: Weekly boost
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly boost of 2 Gy to the tumor bed
Study: 22492586
Drug: Canagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50 mg QD
Study: 22226086
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg QD
Study: 22492586
Drug: Canagliflozin 200
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin 200 mg QD
Study: 22492586
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg QD
Study: 22226086
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg BID
Study: 22492586
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg QD
Study: 17974534
Drug: Exacta small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exacta small screw titanium implants (Exacta MS series conical profile, diameter 3.3 mm, length 7.0 mm)
Study: 16330290
Drug: Glimepiride (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (titrated from 2 to 4 to 8 mg/d over 6 weeks, followed by 20 weeks of maintenance therapy)
Study: 9628124
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg L-846
Study: 9628124
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg L-846
Study: 7839093
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (40 mg three times daily, loading dose 80 mg) and amoxicillin (2 g three times daily for 3 days, then 20 mg omeprazole twice daily and 1 g amoxicillin twice daily orally for 11 days)
Study: 7839093
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg three times daily, loading dose 80 mg) intravenously for 3 days and 20 mg omeprazole twice daily and 1 g amoxicillin twice daily orally for 11 days
Study: 3279756
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 6 PM
Study: 3279756
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 10 PM
Study: 31477542
Drug: Intensive TBS
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive TBS (3 intermittent TBS treatments per day for 3 days in week 1, 3 treatments a day for 2 days in week 2, and 3 treatments in 1 day in week 3 and in week 4)